Dr. Park Group — Seongnam, Korea
Five companies, one founder.
Licensed medical devices, professional cosmeceuticals and viral vector manufacturing from one site in Seongnam, with two research companies presenting their work on their own sites. All five were founded by Dr. Yongho Park.
The companies→01The founder
Built in sequence, under one name each.
Dr. Yongho Park founded GANA R&D in 2014 to manufacture dermal fillers under a Korean medical device licence. GANA Cosmetic followed in 2017 for professional skincare, and Dr. Park CDMO in 2019 to bring viral vector manufacturing onto the same site in Seongnam. Dr. Park Pharmaceutical and NeuroDP Therapeutics present their research on their own sites.
He remains the principal decision-maker in each company. Partners and buyers deal with him directly, and decisions are taken without a committee.
- 2014GANA R&D Co., Ltd. incorporated. MFDS medical device manufacturing licence No. 4490.
- 2017GANA Cosmetic Co., Ltd. incorporated.
- 2019Dr. Park CDMO incorporated.
- 2025Phase 1 viral vector facility completed in August. Thermo Fisher Scientific selected to equip it.
- 2026cGMP certification targeted for the viral vector facility.
On the record
02What we make
Skin, tissue, cell and gene. Each stated on its own.
The companies work at different depths of the body. The status of each is given separately: two depths are made and registered, one is built and awaiting certification, and two companies are at the research stage.
Skin
Dermal fillers in hyaluronic acid, PLLA, PCL and calcium, plus PN / PDRN, and professional cosmeceuticals.
Made and registered.
By · GANA R&D · GANA Cosmetic
Tissue
Hydrogel and foam wound dressings for hospitals and long-term care.
Made and registered, including domestic-sale approval in Korea.
By · GANA R&D
Cell and gene
AAV and other viral vectors, plasmid and recombinant protein for gene therapy developers.
Facility completed in 2025. cGMP certification targeted for 2026.
By · Dr. Park CDMO
Research
Genomic and telomere research, and neurotherapeutics, each presented on the company’s own site.
Research stage.
By · Dr. Park Pharmaceutical · NeuroDP Therapeutics
We do not claim one technology platform across these depths. We state that the same founder stands behind each company, and that three of them manufacture on one site.
03The companies
Five companies, each under its own name.
Licences and registrations belong to the company that holds them. They are listed under that name here, and in full on each company's own site.
01 GANA R&D Medical devices
Fillers and wound dressings, made and registered.
Dermal fillers across four chemistries, and hydrogel and foam wound dressings, formulated, filled and registered under its own name, with contract manufacture for partner brands.
- Serves
- Clinics, hospitals, medical distributors and brand partners.
- Status
- Licensed manufacturer. Products made and registered.
On the record
- MFDS manufacturing licence No. 4490, held since 2014
- GMP conformity KCL-ABBA-19926, valid to 3 March 2027
- EUDAMED manufacturer SRN KR-MF-000037221
- MHRA manufacturer registration MAN_ID 32678
- 34 active product registrations across South Korea, Russia, Brazil and the United Kingdom
02 GANA Cosmetic Cosmeceuticals
Cosmeceuticals for clinics and professional distributors.
Cosmeceutical product development, OEM / ODM manufacture and private label for professional skincare.
- Serves
- Clinics, aesthetic distributors and ODM partners, in four languages.
- Status
- Operating brand and B2B supplier.
On the record
- Product notifications and quality documentation are presented on its own site
03 Dr. Park CDMO Viral vector manufacturing
Viral vectors, plasmid and protein. cGMP targeted for 2026.
Viral vectors (AAV, adenovirus, lentivirus), GMP plasmid, recombinant protein and peptide, from process development through engineering batches.
- Serves
- Gene therapy developers and biotech partners.
- Status
- Phase 1 viral vector facility completed August 2025. Process development and engineering batches available now. cGMP certification targeted for 2026; clinical supply can be contracted once certified.
On the record
- Founded solely by Dr. Park, without external investment
- Facility and equipment specifications are published on its own site
04 Dr. Park Pharmaceutical Genomic and telomere research
Research in genomics and telomere biology.
Research programmes in genomics and telomere biology, presented on its own site.
- Serves
- Research and licensing partners.
- Status
- Research company founded by Dr. Yongho Park.
On the record
- Programmes and publications are presented on its own site
05 NeuroDP Therapeutics Neurotherapeutics
Research in neurotherapeutics.
Research programmes in neurotherapeutics, presented on its own site.
- Serves
- Research and licensing partners.
- Status
- Research company founded by Dr. Yongho Park.
04On film
The Seongnam site, on film.
Phase 1 viral vector facility, completed August 2025. Shot on site. No stock footage.
Watch the film
05Contact
Write to the company, not the group.
Enquiries are answered by the company that makes the product or runs the research. Pick the line that matches yours.
- GANA R&D Device and distribution enquiries +82-31-733-0242 Contact GANA R&D→
- GANA Cosmetic Cosmetic product and ODM enquiries contact@gana-cosmetics.com Contact GANA Cosmetic→
- Dr. Park CDMO Vector, plasmid and protein manufacturing enquiries +82-31-734-0077 Contact Dr. Park CDMO→
- Dr. Park Pharmaceutical Research and licensing enquiries drpgt.com Contact Dr. Park Pharmaceutical→
- NeuroDP Therapeutics Research and licensing enquiries ndpgt.com Contact NeuroDP Therapeutics→
Need a registration number?
GANA R&D publishes every device registration with a public lookup path.